WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Xi, Lula Send Congratulatory Letters to Seminar Involving CPC, Workers' Party of BrazilDeveloped countries must face up to their responsibilities to address climate changeCommentary: Sowing discord, fanning flames no good for peace in Middle EastAnger as new Rector claims Glasgow University 'colludes in murder of innocents'London mayoral hustings descends into mayhem as Sadiq Khan is heckled by man about the 'absolute dooXi Focus: Xi Jinping Meets Ma YingChris Packham joins ecoResidents of BeijingChina Focus: Record Qingming holiday box office heats up for May Day moviegoing frenzyBritain's Gibraltar concessions with Spain just to reach a post